Management of Alcohol Use Disorder in Patients With Alcoholic Liver Disease

被引:8
作者
Murthy, Pratima [1 ,3 ]
Shadakshari, Darshan [2 ]
Mahadevan, Jayant [2 ]
Chand, Prabhat Kumar [2 ]
机构
[1] Natl Inst Mental Hlth & Neurosci, Bangalore, India
[2] Natl Inst Mental Hlth & Neurosci, Ctr Addict Med, Dept Psychiat, Bangalore, India
[3] Natl Inst Mental Hlth & Neurosci, Bangalore, India
关键词
alcohol use disorder; alcoholic liver disease; diagnosis; pharma-cotherapy; psychotherapy; DOUBLE-BLIND; ABSTINENCE; BACLOFEN; NALTREXONE; CIRRHOSIS; RISK; PHARMACOTHERAPY; TRANSPLANTATION; INDIVIDUALS; MAINTENANCE;
D O I
10.1016/j.jceh.2022.04.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Alcohol use disorder (AUD) is a common condition that develops on the background of heavy alcohol use and is characterised by the loss of control over alcohol use and a compulsion to use alcohol, often despite negative con-sequences. AUD is a leading cause for the resumption of alcohol use in patients with alcoholic liver disease (ALD) after treatment. Hence it is essential to screen all patients with ALD for the presence of AUD. Screening tools such as alcohol use disorders identification test (AUDIT) and AUDIT-C are used, following which the diagnosis and severity of AUD are determined using DSM-5 criteria. The management of AUD in patients with ALD is best carried out using an integrated approach involving psychiatrists and gastroenterologists/hepatologists. The treatment most often involves a combination of pharmacotherapy and psychosocial interventions which try to achieve and maintain abstinence. Although, there is limited evidence, Baclofen is the first line pharmacological agent for long-term management of AUD in patients with ALD. Intensive psychological interventions such as motivation enhancement therapy and cognitive behavioural therapy are also seen to be beneficial. Treatment retention and follow-up are vital and can positively influence outcomes. (J CLIN EXP HEPATOL 2022;12:1514-1526)
引用
收藏
页码:1514 / 1526
页数:13
相关论文
共 89 条
[1]   Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study [J].
Addolorato, Giovanni ;
Leggio, Lorenzo ;
Ferrulli, Anna ;
Cardone, Silvia ;
Vonghia, Luisa ;
Mirijello, Antonio ;
Abenavoli, Ludovico ;
D'Angelo, Cristina ;
Caputo, Fabio ;
Zambon, Antonella ;
Haber, Paul S. ;
Gasbarrini, Giovanni .
LANCET, 2007, 370 (9603) :1915-1922
[2]   Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows [J].
Addolorato, Giovanni ;
Vassallo, Gabriele A. ;
Mirijello, Antonio ;
Gasbarrini, Antonio .
NEUROTHERAPEUTICS, 2020, 17 (01) :127-141
[3]   Treatment of alcohol use disorders in patients with alcoholic liver disease [J].
Addolorato, Giovanni ;
Mirijello, Antonio ;
Barrio, Pablo ;
Gual, Antoni .
JOURNAL OF HEPATOLOGY, 2016, 65 (03) :618-630
[4]   Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center [J].
Addolorato, Giovanni ;
Mirijello, Antonio ;
Leggio, Lorenzo ;
Ferrulli, Anna ;
D'Angelo, Cristina ;
Vassallo, Gabriele ;
Cossari, Anthony ;
Gasbarrini, Giovanni ;
Landolfi, Raffaele ;
Agnes, Salvatore ;
Gasbarrini, Antonio .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 (09) :1601-1608
[5]   Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders [J].
Agabio, Roberta ;
Leggio, Lorenzo .
FRONTIERS IN PSYCHIATRY, 2018, 9
[6]   Prescribing Medications in Patients with Decompensated Liver Cirrhosis [J].
Amarapurkar, Deepak N. .
INTERNATIONAL JOURNAL OF HEPATOLOGY, 2011, 2011
[7]  
[Anonymous], ACAMPROSATE SAFE USE
[8]  
[Anonymous], EFFECT NALTREXONE AC
[9]  
[Anonymous], GABAPENTIN TREAT ITC
[10]   Naltrexone for the management of alcohol dependence [J].
Anton, Raymond F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (07) :715-721